Dacogen

decitabine ·
AUTHORISED IN THE EU

What Dacogen is used for

Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Dacogen
Active substance
decitabine
Disease area
Leukemia, Myeloid
Medicine group
Antineoplastic agents
ATC code
L01BC08
Authorised in the EU since
2012

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Dacogen used for?

Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.

What is the active substance in Dacogen?

Dacogen contains decitabine.

Who makes Dacogen?

The EU marketing authorisation holder is .

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.